FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Breath Test Predicts Immunotherapy Response to Mesothelioma
Researchers in the Netherlands are touting a novel breath test for mesothelioma patients to better predict response to the immunotherapy combination of nivolumab and ipilimumab that was approved recently for first-line treatment of the disease.
They believe exhaled breath analysis using electronic technology – known as eNose – can differentiate between responders and nonresponders before treatment begins, saving many patients from unnecessary side effects.
There currently are no biomarkers for mesothelioma that can accurately predict the effectiveness of these types of immunotherapy drugs, known as immune checkpo...
Source: Asbestos and Mesothelioma News - June 10, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Immunotherapy Likely New Standard in Advanced Esophageal Cancer Immunotherapy Likely New Standard in Advanced Esophageal Cancer
Nivolumab with chemotherapy or nivolumab with ipilimumab improved overall survival as compared with standard chemotherapy in advanced ESCC.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU
Nivolumab plus ipilimumab showed superior overall survival versus standard-of-care chemotherapy in patients with unresectable malignant mesothelioma.News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma
(SWOG Cancer Research Network) Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2021 Category: Cancer & Oncology Source Type: news
' Encouraging' Data on Ipilimumab Plus Anti-PD-1 in Metastatic Melanoma'Encouraging' Data on Ipilimumab Plus Anti-PD-1 in Metastatic Melanoma
For patients with advanced melanoma resistant to anti-PD-L1 monotherapy, combining the CTLA-4 inhibitor ipilimumab with an anti-PD-1 agent ' should be favored ' over ipilimumab alone as second-line immunotherapy, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Benefits of immunotherapy combination persist for more than six years in advanced melanoma
(Dana-Farber Cancer Institute) In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive a median of six and a half years after treatment. The results, stemming from the CheckMate 067 clinical trial, represent a new landmark in survival rates for patients with melanoma treated with immune checkpoint inhibitor drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 27, 2021 Category: Cancer & Oncology Source Type: news
A Look at Three Decades of Real-World Mesothelioma Statistics
Despite clinical trials that often produce inflated expectations, real-world survival rates for pleural mesothelioma have failed to advance significantly over the past three decades, according to one recent study in Canada.
Celebrated treatment advances have fallen short for the average patient diagnosed with this rare cancer caused by exposure to asbestos.
“This is a story about a lack of progress. What we’ve seen is kind of underwhelming,” Dr. Paul Wheatley-Price, associate professor of medicine at University of Ottawa and thoracic oncologist at The Ottawa Hospital Cancer Centre, told The Mesothelioma Center ...
Source: Asbestos and Mesothelioma News - May 11, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Nivolumab-ipilimumab not cost effective for advanced non-small-cell lung cancer in the US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news
Phase III Trial of Durvalumab for Mesothelioma Underway
The U.S. Food and Drug Administration will be closely watching the latest, international phase III clinical trial for unresectable pleural mesothelioma involving the immunotherapy drug durvalumab.
FDA approval may be coming soon.
“It looks very promising,” Dr. Arkadiusz Dudek, of Regions Hospital Cancer Care Center in St. Paul, Minnesota, told The Mesothelioma Center at Asbestos.com. “The hope is to have the regimen approved by the FDA as front-line therapy. There is a real need today for more options with mesothelioma.”
The goal of the randomized trial – officially known as DREAM3R – is to determine h...
Source: Asbestos and Mesothelioma News - April 1, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Study: Which Mesothelioma Patients Will Immunotherapy Benefit?
This study also is designed to better understand the biological mechanisms affecting the immune system.
The goal is to use both the cellular organization and molecular pathways to develop a test that can predict the response to the checkpoint inhibitor drugs. Upon completion, a clinical trial would follow, in which treatment would depend on the results of the individual’s test.
“Within the next year or two, we’ll have a good idea of whether these components are working,” Burt said.
The post Study: Which Mesothelioma Patients Will Immunotherapy Benefit? appeared first on Mesothelioma Center - Vital S...
Source: Asbestos and Mesothelioma News - February 23, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news
FDA Fast-Tracks Mesothelioma Vaccine Development
The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors.
This designation is expected to expedite the regulatory approval process. The vaccine’s developer, Targovax, a small biotech company that focuses on oncolytic viruses, sees this as an early endorsement from the FDA.
“Yes, this opens the door for us,” Dr. Magnus Jaderberg, chief medical officer of Targovax, told The Mesothelioma Center at Asbestos.com. “It validates what the FDA believes is a potentially promising drug for this d...
Source: Asbestos and Mesothelioma News - February 19, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news
Combo Immunotherapy in NSCLC: Not These Two Drugs Combo Immunotherapy in NSCLC: Not These Two Drugs
Pembrolizumab monotherapy remains a standard of care, after trial results show that adding ipilimumab conveys no benefits but incurs greater toxicity.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 10, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Opdivo Study Offers Hope to Relapsed Mesothelioma Patients
A recent study out of the United Kingdom finds patients with relapsed malignant mesothelioma can be treated effectively with single-agent nivolumab, safely improving overall and progression-free survival.
Nivolumab, also known by the brand name Opdivo, is an immunotherapy drug already being used successfully with non-small cell lung cancer.
It is the first drug to show a significant survival advantage for relapsed mesothelioma in a phase III clinical trial, according to principal investigator Dr. Dean Fennell, medical oncologist at the University of Leicester in England.
“This is very encouraging news,” Fennell told Th...
Source: Asbestos and Mesothelioma News - February 4, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
